Yabao Pharmaceutical Group Co., Ltd. (600351.SH) Latest Company News

Sep 16, 2026, 07:33 UTC
Shanxi Yabao Investment Group, controlling shareholder of Yabao Pharmaceutical, completed a stock pledge repo transaction, raising its cumulative pledged shares to 38.45 million shares, or 40.77% of its holding and 5.56% of the company's total share capital.
Source:
- finance.sina.cn
Sep 11, 2026, 07:50 UTC
Yabao Pharmaceutical repurchased 200,000 shares for the first time on September 11, 2026, at 6.58-6.59 yuan per share for a total of 1.317 million yuan, under a 100-200 million yuan buyback program to cancel shares and reduce registered capital.
Source:
- finance.sina.cn
Aug 28, 2026, 08:43 UTC
Yabao Pharmaceutical adjusted the upper limit of its share buyback price to 6.75 yuan per share, effective from September 1, 2026, due to the implementation of the 2026 interim dividend distribution.
Source:
- finance.sina.cn
Aug 1, 2026, 00:33 UTC
On August 1, 2026, 47 Chinese A-share companies disclosed various stages of stock buyback progress, including shareholder proposals, initial plans, implementation updates, and completed buybacks.
Source:
- finance.sina.cn
Jul 31, 2026, 07:53 UTC
Yabao Pharmaceutical's wholly-owned subsidiary Yabao Pharmaceutical Sichuan Co., Ltd. received drug registration certificates from the National Medical Products Administration for two specifications of Levocetirizine Hydrochloride Oral Solution, which is indicated for various allergic symptoms and can be used in people aged 6 months and above.
Source:
- finance.sina.cn
Jul 31, 2026, 07:53 UTC
Yabao Pharmaceutical announced a plan to repurchase its own shares for 100 million to 200 million yuan at a price not exceeding 6.95 yuan per share, with the repurchased shares to be cancelled to reduce registered capital, funded by its own funds, within 12 months after shareholder approval.
Source:
- finance.sina.cn
Jul 2, 2026, 07:34 UTC
Yabao Pharmaceutical received a drug registration certificate for its Crisaborole Ointment from the National Medical Products Administration.
Source:
- finance.sina.cn

600351.SH

Shanxi Yabao Investment Group, controlling shareholder of Yabao Pharmaceutical, completed a stock pledge repo transaction, raising its cumulative pledged shares to 38.45 million shares, or 40.77% of its holding and 5.56% of the company's total share capital.

Yabao Pharmaceutical repurchased 200,000 shares for the first time on September 11, 2026, at 6.58-6.59 yuan per share for a total of 1.317 million yuan, under a 100-200 million yuan buyback program to cancel shares and reduce registered capital.

Yabao Pharmaceutical adjusted the upper limit of its share buyback price to 6.75 yuan per share, effective from September 1, 2026, due to the implementation of the 2026 interim dividend distribution.

On August 1, 2026, 47 Chinese A-share companies disclosed various stages of stock buyback progress, including shareholder proposals, initial plans, implementation updates, and completed buybacks.

Yabao Pharmaceutical announced a plan to repurchase its own shares for 100 million to 200 million yuan at a price not exceeding 6.95 yuan per share, with the repurchased shares to be cancelled to reduce registered capital, funded by its own funds, within 12 months after shareholder approval.

Yabao Pharmaceutical received a drug registration certificate for its Crisaborole Ointment from the National Medical Products Administration.